Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II lurbinectedin in selected advanced solid tumors
2014-003773-42Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Jan 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lurbinectedin in small cell lung cancer (SCLC), head and neck cancer (HNC), apudoma (NET) and 6 more, sponsored by PharmaMar. Primary endpoint: Overall response rate. Started Jan 2015; status: completed.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)head and neck cancer (HNC)apudoma (NET)biliary cancerendometrial cancer (EC)
Beyond the preview
Go deeper on 2014-003773-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003773-42.